Dr. Edward Pearson explores the latest advancement in anti-CD38 therapy: subcutaneous delivery of isatuximab via on-body injector. He reviews clinical evidence on efficacy, safety, and patient preference, and shares how he anticipates this innovation to impact clinic workflows, care teams, and the overall multiple myeloma patient experience.
This episode is part of the micro-series, Optimizing Care in Multiple Myeloma: Perspectives on Treatment and Delivery Innovation.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

Brook Cox, BSN, RN, OCN, an oncology nurse and infusion room supervisor, shares how subcutaneous administration of anti-CD38 therapy has transformed infusion center operations, improved patient flow, and created both opportunities and challenges for nursing teams caring for patients with multiple myeloma.
This episode is part of the micro-series, Optimizing Care in Multiple Myeloma: Perspectives on Treatment and Delivery Innovation.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

Dr. Edward Pearson reviews pivotal clinical trial data supporting anti-CD38-based regimens and explores how clinicians can balance efficacy, tolerability, and quality of life when managing high-risk and transplant-ineligible multiple myeloma.
This episode is part of the micro-series, Optimizing Care in Multiple Myeloma: Perspectives on Treatment and Delivery Innovation.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

Dr. Edward Pearson discusses the growing role of anti-CD38-based quadruplet therapy and key considerations influencing frontline therapy selection for patients with newly diagnosed, transplant-ineligible multiple myeloma.
This episode is part of the micro-series, Optimizing Care in Multiple Myeloma: Perspectives on Treatment and Delivery Innovation.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

In the final episode of this four-part series, Dr. Mohit Narang looks ahead to emerging innovations in multiple myeloma. Learn about new therapeutic targets, MRD testing, sequencing strategies, and personalized approaches that aim to optimize outcomes and bring us closer to functional cures.
This episode is part of the Micro-Series, Multiple Myeloma in 2025: Transformative Progress, the Latest Innovation, and Future Opportunities.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

In part three of four, Dr. Mohit Narang explores how bispecific antibodies and other advanced treatments are being implemented in real-world community oncology practices. Discover the operational challenges, safety considerations, and strategies that enable community oncology centers to expand access to these transformative therapies for the broader patient population.
This episode is part of the Micro-Series, Multiple Myeloma in 2025: Transformative Progress, the Latest Innovation, and Future Opportunities.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

In part two of four, Dr. Mohit Narang examines the rapidly evolving treatment landscape for multiple myeloma. Tune in to learn how therapy has progressed from doublets to quadruplets, reshaping the role of autologous stem cell transplant, and the impact of the latest immune therapies, including monoclonal antibodies, bispecific antibody therapy, and CAR-T approaches.
This episode is part of the Micro-Series, Multiple Myeloma in 2025: Transformative Progress, the Latest Innovation, and Future Opportunities.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

In part one of four, Dr. Mohit Narang from Maryland Oncology Hematology provides a foundational overview of multiple myeloma.  Tune in to learn how its incidence has evolved over the past thirty years, what we know today about disease risk factors, and the molecular mechanisms underlying multiple myeloma pathophysiology and diagnosis. 
This episode is part of the Micro-Series, Multiple Myeloma in 2025: Transformative Progress, the Latest Innovation, and Future Opportunities.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

Join Dr. Paul Conkling and Dr. Akash Mukherjee as they explore CAR-T Therapy from design of treatment through the patient journey.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.